Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 19, 2006

Nastech Pharmaceutical's Intranasal Insulin Formulation Enters into Clinical Trial

  • Nastech Pharmaceutical initiated a Phase I pharmacokinetic study designed to evaluate the safety, bioavailability, and glucose response of Nastech’s rapid-acting intranasal insulin formulation. The study will compare Nastech’s intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera® (insulin human [rDNA origin]) Inhalation Powder.

    Nastech believes its insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long-term toxicity associated with the inhalation of insulin.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »